Evidence map›Paper›PMID 42611989›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

The immunophenotype and proviral landscape of HIV-infected CD4 T cells during antiretroviral therapy.

Cyrille L Delley, Sakshi Shah, Kevin M Joslin, Yujung P Park, Benjamin Demaree, Michael P Busch, Mars Stone, Steven G Deeks, Eli A Boritz, Adam R Abate and 1 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Cyrille L DelleyDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158.ORCID 0000-0002-3599-5701
Sakshi ShahDepartment of Bioengineering, University of California, Berkeley, California Institute for Quantitative Biosciences, Berkeley, CA 94720.ORCID 0000-0002-8378-7253
Kevin M JoslinDepartment of Bioengineering, University of California, Berkeley, California Institute for Quantitative Biosciences, Berkeley, CA 94720.
Yujung P ParkDepartment of Bioengineering, University of California, Berkeley, California Institute for Quantitative Biosciences, Berkeley, CA 94720.ORCID 0009-0002-5747-0604
Benjamin DemareeDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158.
Michael P BuschVitalant Research Institute, San Francisco, CA 94105.ORCID 0000-0002-1446-125X
Mars StoneVitalant Research Institute, San Francisco, CA 94105.ORCID 0000-0001-5619-2767
Steven G DeeksDepartment of Medicine, University of California, San Francisco, CA 94158.
Eli A BoritzVirus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.ORCID 0000-0003-4633-4594
Adam R AbateDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158.ORCID 0000-0001-9614-4831
Iain C ClarkDepartment of Bioengineering, University of California, Berkeley, California Institute for Quantitative Biosciences, Berkeley, CA 94720.ORCID 0000-0001-9082-0253

Funding

HIV persistence in vivoZIAAI005131 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BORITZ, ELI · 2017 to 2025
$14.5M
Sorting and Sequencing Latent Reservoirs in HIV+ Opioid UsersR01DA059551 · NIDA · J. DAVID GLADSTONE INSTITUTES · PI Adam R. Abate, Iain Clark · 2023 to 2026
$6.3M
Single Cell Transcriptomic and Epigenetic Analysis of CD4 T Cells Harboring Latent HIV during Antiretroviral TherapyK22AI152644 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI CLARK, IAIN · 2021 to 2022
$264k
Bill and Melinda Gates Foundation (GF) INV-008500Bill & Melinda Gates Foundation INV-008500Chan Zuckerberg Initiative (CZI) InvestigatorHHS | National Institutes of Health (NIH) K22AI152644 1R01DA059551-01HHS | National Institutes of Health (NIH) ZIA AI005131Intramural NIH HHS ZIA AI005131NIAID NIH HHS K22 AI152644NIDA NIH HHS R01 DA059551
6 · The paper itself

Abstract

In individuals on effective antiretroviral therapy (ART), integrated HIV proviruses persist within CD4 T cells, forming a viral reservoir that rebounds if treatment is stopped. Identifying and targeting these rare, infected cells is critical for advancing therapies, but methods to study reservoir cells are limited, and their unique properties remain largely unknown. We applied DAb-seq, a high-throughput method that combines single-cell DNA and surface protein sequencing, to profile ~527,000 CD4 T cells from the blood of six individuals on ART. Infected cells were distributed across all CD4 T cell subsets but were enriched in central memory subsets and in a CD4 subset with Th17-like signatures expressing high levels of integrin β7. Attempts to identify surface markers distinguishing infected from uninfected cells revealed epitopes that largely reflected the subsets most enriched for infection. However, while central memory T cells harbored the majority of HIV, proviruses with a greater number of genomic regions were enriched relative to their more defective counterparts in the CD4 Naïve, transitional memory (Ttm), and regulatory (Treg) subsets, suggesting that these subsets differentially maintain more complete proviral genomes. In summary, we developed DAb-seq as an open-source platform to link proviral sequences to cellular phenotypes, revealing heterogeneity in surface protein expression and proviral fate across infected subsets.

Indexed as

Anti-Retroviral AgentsCD4-Positive T-LymphocytesHIV-1HIV InfectionsProvirusesHumansImmunophenotypingAnti-Retroviral AgentsDAb-seqhigh-throughput microfluidicsHIV persistencesingle cell analysis

Identifiers

PMID42611989
PMCPMC13505993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.